177 related articles for article (PubMed ID: 37811115)
1. Briumvi: a breakthrough in the treatment of relapsing multiple sclerosis: a review.
Azhar A; Taimuri MA; Shamat SF; Ikram A; Ali S; Ali T; Khabir Y
Ann Med Surg (Lond); 2023 Oct; 85(10):4909-4912. PubMed ID: 37811115
[TBL] [Abstract][Full Text] [Related]
2. Ublituximab: A new FDA-approved anti-CD20 mAb for relapsing forms of multiple sclerosis.
Boldrini VO; Mader S; Kümpfel T; Meinl E
Mult Scler Relat Disord; 2023 Jul; 75():104733. PubMed ID: 37156035
[TBL] [Abstract][Full Text] [Related]
3. Ublituximab-xiiy as a treatment option for relapsing multiple sclerosis.
Jakimovski D; Weinstock-Guttman B; Zivadinov R
Expert Rev Neurother; 2023; 23(12):1053-1061. PubMed ID: 37842819
[TBL] [Abstract][Full Text] [Related]
4. Ublituximab: First Approval.
Lee A
Drugs; 2023 Apr; 83(5):455-459. PubMed ID: 36920653
[TBL] [Abstract][Full Text] [Related]
5. The ULTIMATE trials: are there advantages of ublituximab over teriflunomide in relapsing multiple sclerosis?
Doggrell SA
Expert Opin Biol Ther; 2022 Nov; 22(11):1339-1343. PubMed ID: 36317532
[TBL] [Abstract][Full Text] [Related]
6. Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis.
Steinman L; Fox E; Hartung HP; Alvarez E; Qian P; Wray S; Robertson D; Huang D; Selmaj K; Wynn D; Cutter G; Mok K; Hsu Y; Xu Y; Weiss MS; Bosco JA; Power SA; Lee L; Miskin HP; Cree BAC;
N Engl J Med; 2022 Aug; 387(8):704-714. PubMed ID: 36001711
[TBL] [Abstract][Full Text] [Related]
7. The Development of Ofatumumab, a Fully Human Anti-CD20 Monoclonal Antibody for Practical Use in Relapsing Multiple Sclerosis Treatment.
Hauser SL; Kappos L; Bar-Or A; Wiendl H; Paling D; Williams M; Gold R; Chan A; Milo R; Das Gupta A; Karlsson G; Sullivan R; Graham G; Merschhemke M; Häring DA; Vermersch P
Neurol Ther; 2023 Oct; 12(5):1491-1515. PubMed ID: 37450172
[TBL] [Abstract][Full Text] [Related]
8. Systematic Review of Safety and Efficacy of Second- and Third-Generation CD20-Targeting Biologics in Treating Immune-Mediated Disorders.
Kaegi C; Wuest B; Crowley C; Boyman O
Front Immunol; 2021; 12():788830. PubMed ID: 35185862
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the Efficacy and Safety of Anti-CD20 B Cells Depleting Drugs in Multiple Sclerosis.
Cotchett KR; Dittel BN; Obeidat AZ
Mult Scler Relat Disord; 2021 Apr; 49():102787. PubMed ID: 33516134
[TBL] [Abstract][Full Text] [Related]
10. [B-cell depletion in the therapy of multiple sclerosis: ofatumumab is a new player].
Pukoli D; Vécsei L
Ideggyogy Sz; 2022 May; 75(5-06):163-169. PubMed ID: 35819344
[TBL] [Abstract][Full Text] [Related]
11. Ublituximab (Briumvi) for relapsing multiple sclerosis.
Med Lett Drugs Ther; 2023 Mar; 65(1671):36-38. PubMed ID: 36877282
[No Abstract] [Full Text] [Related]
12. The potential role for ocrelizumab in the treatment of multiple sclerosis: current evidence and future prospects.
Sorensen PS; Blinkenberg M
Ther Adv Neurol Disord; 2016 Jan; 9(1):44-52. PubMed ID: 26788130
[TBL] [Abstract][Full Text] [Related]
13. Anti-CD20 Agents for Multiple Sclerosis: Spotlight on Ocrelizumab and Ofatumumab.
Florou D; Katsara M; Feehan J; Dardiotis E; Apostolopoulos V
Brain Sci; 2020 Oct; 10(10):. PubMed ID: 33092190
[TBL] [Abstract][Full Text] [Related]
14. Anti-CD20 Monoclonal Antibodies for Relapsing and Progressive Multiple Sclerosis.
Sellebjerg F; Blinkenberg M; Sorensen PS
CNS Drugs; 2020 Mar; 34(3):269-280. PubMed ID: 31994023
[TBL] [Abstract][Full Text] [Related]
15. Rituximab for relapsing-remitting multiple sclerosis.
He D; Guo R; Zhang F; Zhang C; Dong S; Zhou H
Cochrane Database Syst Rev; 2013 Dec; (12):CD009130. PubMed ID: 24310855
[TBL] [Abstract][Full Text] [Related]
16. Ocrelizumab: a new milestone in multiple sclerosis therapy.
Mulero P; Midaglia L; Montalban X
Ther Adv Neurol Disord; 2018; 11():1756286418773025. PubMed ID: 29774057
[TBL] [Abstract][Full Text] [Related]
17. Anti-CD20 B Cell Treatment for Relapsing Multiple Sclerosis.
Roach CA; Cross AH
Front Neurol; 2020; 11():595547. PubMed ID: 33551958
[TBL] [Abstract][Full Text] [Related]
18. B cell depletion in the treatment of multiple sclerosis.
Myhr KM; Torkildsen Ø; Lossius A; Bø L; Holmøy T
Expert Opin Biol Ther; 2019 Mar; 19(3):261-271. PubMed ID: 30632834
[TBL] [Abstract][Full Text] [Related]
19. CD20 monoclonal antibodies for the treatment of multiple sclerosis: up-to-date.
Ancau M; Berthele A; Hemmer B
Expert Opin Biol Ther; 2019 Aug; 19(8):829-843. PubMed ID: 31027436
[TBL] [Abstract][Full Text] [Related]
20. Anti-CD20 therapies in multiple sclerosis: From pathology to the clinic.
de Sèze J; Maillart E; Gueguen A; Laplaud DA; Michel L; Thouvenot E; Zephir H; Zimmer L; Biotti D; Liblau R
Front Immunol; 2023; 14():1004795. PubMed ID: 37033984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
